Opinion|Videos|September 10, 2024
Oral vs. Injectable HMAs: Convenience and Efficacy in Higher Risk MDS
Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For patients with higher-risk myelodysplastic syndromes (MDS), what are some of the primary challenges in conducting research and developing novel therapies for this patient population?
- How do social support and logistical factors, such as the ability to access clinics for extended periods for injectable hypomethylating agents (HMAs), affect treatment adherence and outcomes in patients with higher-risk MDS?
- Given that HMAs are the backbone of treatment for higher-risk MDS, how do oral options such as decitabine-cedazuridine and other emerging therapies address the need for more convenient administration while maintaining efficacy?
Advertisement
Related to this article
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
SURPASS-CVOT data show fewer deaths or HF events with tirzepatide vs dulaglutide in patients with HF, driven largely by mortality.
Subcutaneous mosunetuzumab plus polatuzumab vedotin boosts responses in relapsed large B-cell lymphoma, helping community oncology care.
Using baseline samples from 177 patients in the VISION/HO141 trial, researchers built a functional prognostic model for CLL that outperformed the CLL-IPI.
Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
Advertisement
Advertisement
Trending on AJMC
1
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
2
FDA Approves First Treatment for BCG-Unresponsive Bladder Cancer
3
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
4
Admilparant Phase 3 ALOFT-IPF Trial Meets Primary End Point in IPF
5